Clinical trials: Pancreatic Cancer
Advanced Pancreatic Cancer
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
To compare, in patients with advanced pancreatic cancer, the effects of IMM-101 in combination with gemcitabine to gemcitabine alone on safety and tolerability (including QoL), clinical signs and symptoms of disease, selected…
- Trial name
- NCT01303172
- Testing
- IMM-101, Gemcitabine
- Where
- 21 sites in Cyprus, Ireland and 3 more
- Volunteers
- 110 people
- Sponsor
- Immodulon Therapeutics Ltd
MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have…
- Trial name
- NCT06188702
- Testing
- S095035, TNG462
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Servier Bio-Innovation LLC
Gastrointestinal Neoplasms, Cholangiocarcinoma
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Phase 1a - Explore safety and establish the maximum tolerated dose (MTD)/recommended dose levels for phase Ib expansion phase of BI 905711 based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the…
- Conditions
- Gastrointestinal Neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms
- Trial name
- NCT04137289
- Testing
- BI 905711
- Where
- 18 sites in United States, Belgium and 6 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors, Solid Tumors
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
This will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed talazoparib liquid-filled soft gelatin capsule (soft…
- Conditions
- Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer
- Trial name
- NCT04672460
- Testing
- TALZENNA capsule, Talazoparib soft gel capsule
- Where
- 31 sites in United States, Australia
- Volunteers
- 73 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Pancreatic Adenocarcinoma
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in…
- Conditions
- Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05585320
- Testing
- IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
- Where
- 20 sites in United States
- Volunteers
- 209 people
- Sponsor
- Immuneering Corporation
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Head and Neck Neoplasm, Prostatic Neoplasm
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography [PET] scans due to advanced non-hematologic…
- Conditions
- Head and Neck Neoplasm, Prostatic Neoplasm, Pancreatic Neoplasm
- Trial name
- NCT00666926
- Testing
- PF00562271
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 99 people
- Sponsor
- Verastem, Inc.
Adenocarcinoma
AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer
The purpose of this study is to assess the effect and safety of AXP107-11 alone, and in combination with gemcitabine standard therapy, in patients with advanced or metastatic cancer of the pancreas.
- Trial name
- NCT01182246
- Testing
- AXP107-11
- Where
- 2 sites in Sweden
- Volunteers
- 44 people
- Sponsor
- Axcentua Pharmaceuticals AB
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Cancer, Pancreatic Cancer
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
The objectives of this study are: To determine the safety and MTD of CPI-613, when used in combination with Gemcitabine, in cancer patients. To compare the safety and efficacy of CPI-613/Gemcitabine combination vs.
- Conditions
- Cancer, Pancreatic Cancer, Pancreatic Carcinoma
- Trial name
- NCT00907166
- Testing
- CPI-613, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cornerstone Pharmaceuticals
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Advanced Pancreatic Cancer
A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer
The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with with advanced pancreatic cancer and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended…
- Trial name
- NCT04928625
- Testing
- SHR-A1904
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Pancreatic Cancer
Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer
In patients with unresectable advanced pancreatic cancer, non-inferiority of TS-1 monotherapy and superiority of GEM + TS-1 combination therapy to gemcitabine (GEM) will be verified using survival time.
- Trial name
- GEST (NCT00498225)
- Testing
- Gemcitabine plus TS-1, TS-1, Gemcitabine
- Where
- 12 sites in Japan, Taiwan
- Volunteers
- 834 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Pancreatic Neoplasms, Metastases, Neoplasm
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas.
- Trial name
- NCT00035035
- Testing
- GEMZAR, ALIMTA
- Where
- 114 sites in United States, Argentina and 16 more
- Sponsor
- Eli Lilly and Company
Pancreatic Neoplasms, Melanoma
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
In this national Phase I dose-escalation study the safety and tolerability of AP 12009 is evaluated in adult patients with advanced tumors known to overproduce TGF-β2, who are not or no longer amenable to established therapies.
- Conditions
- Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms
- Trial name
- NCT00844064
- Testing
- AP 12009
- Where
- 10 sites in Germany
- Volunteers
- 62 people
- Sponsor
- Isarna Therapeutics GmbH
Gastric Cancer, Gastroesophageal Junction Cancer
Study for AZD4360 in Participants With Advanced Solid Tumours
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06921928
- Testing
- AZD4360
- Where
- 14 sites in United States, China and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Pancreas Cancer, Adenocarcinoma of the Pancreas
The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy
The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy.
- Conditions
- Pancreas Cancer, Adenocarcinoma of the Pancreas, Pancreatic Cancer, Tumor of Pancreas
- Trial name
- GANNON (NCT06282809)
- Testing
- HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- HistoSonics, Inc.
Metastatic Pancreatic Cancer, Pancreatic Cancer
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior…
- Trial name
- PANCRIT®-1 (NCT01956812)
- Testing
- IMMU-107, Gemcitabine
- Where
- 64 sites in United States, Austria and 6 more
- Volunteers
- 334 people
- Sponsor
- Gilead Sciences
Peritoneal Carcinomatosis, Peritoneal Metastases
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT03682744
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sorrento Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.